David Platt - 15 Aug 2024 Form 4 Insider Report for BIOXYTRAN, INC (BIXT)

Role
CEO, Director, 10%+ Owner
Signature
David Platt
Issuer symbol
BIXT
Transactions as of
15 Aug 2024
Net transactions value
+$695,931
Form type
4
Filing time
20 Aug 2024, 17:10:31 UTC
Previous filing
27 Mar 2024
Next filing
18 Nov 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIXT common Purchase $197,522 +1,592,921 +7.9% $0.1240 21,675,939 15 Aug 2024 by NDPD Pharma F1
transaction BIXT common Other $3,511,502 -21,675,939 -100% $0.1620 0 19 Aug 2024 by NDPD Pharma F1, F2
transaction BIXT preferred Other $3,494,162 +4,335,188 $0.8060 4,335,188 19 Aug 2024 by NDPD Pharma F1, F2
transaction BIXT preferred Conversion of derivative security $161,521 +8,973,405 +207% $0.0180 13,308,593 19 Aug 2024 by NDPD Pharma F1
transaction BIXT preferred Other $354,229 +776,817 +5.8% $0.4560 14,085,410 19 Aug 2024 by NDPD Pharma F1, F3
transaction BIXT common Other $411 -411,300 -100% $0.001000 0 19 Aug 2024 by Naomi Platt F4
transaction BIXT preferred Other $411 +82,260 $0.005000 82,260 19 Aug 2024 by Naomi Platt F4
transaction BIXT common Other $43,027 -43,027,274 -100% $0.001000 0 19 Aug 2024 Direct F2
transaction BIXT preferred Other $43,027 +8,605,455 $0.005000 8,605,455 19 Aug 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Total holdings by NDPD Pharma, Inc., an affiliate where the beneficial ownership includes the Companys officers, have been consolidated as indirect ownership in Davis Platt's filing.
F2 A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock.
F3 The shares were acquired through conversion of debt, issued under Rule 3(a)(9).
F4 Total holdings by Naomi Platt, spouse of David Platt.